Divergent metabolic and immunoepigenetic responses in LPS-induced endotoxemia: a dose optimization study in male BALB/c mice [0.03%]
脂多糖诱导的内毒素血症小鼠模型代谢与免疫表观遗传学反应的剂量优化研究
Yogi Prawira,Safarina G Malik,Zakiudin Munasir et al.
Yogi Prawira et al.
Lipopolysaccharide (LPS)-induced endotoxemia is widely used to model sepsis. This study aimed to identify the LPS dose that reliably induces hyperlactatemia, Murine Sepsis Score (MSS) ≥3 (clinically defined sepsis), dose-dependent differen...
Cross-disease immunological comparison reveals shared systemic immune activation across the broader spondyloarthritis spectrum [0.03%]
跨疾病免疫学比较揭示了更广泛的脊柱关节炎谱系中共享的全身免疫激活现象
Koichi Saito,Mitsuhiro Akiyama,Kanako Shimanuki et al.
Koichi Saito et al.
To perform cross-disease immunological comparison across the broader spondyloarthritis (SpA) spectrum and examine their association with disease activity. We analyzed 111 patients with active broader SpA spectrum (ankylosing spondylitis, in...
Low body weight as a risk factor for serious azathioprine-related adverse events in patients with rheumatic diseases [0.03%]
风湿病患者硫唑嘌呤相关严重不良事件的低体重风险因素
Shuhei Yoshida,Kiyoshi Migita,Tomoyuki Asano et al.
Shuhei Yoshida et al.
Serious azathioprine (AZA)-related adverse events (AEs) contribute to treatment discontinuation in patients with rheumatic diseases, although real-world data on patient-related risk factors in Japanese patients remain limited. This study in...
Delayed glucocorticoid initiation is associated with lower stent removal rates in IgG4-related retroperitoneal fibrosis: a retrospective study [0.03%]
皮下型IgG4相关性腹膜后纤维化内支架置入术后糖皮质激素诱导时机对内支架取出率的影响:一项回顾性研究
Ken Nagahata,Masatoshi Kanda,Yuki Hamakawa et al.
Ken Nagahata et al.
IgG4-related retroperitoneal fibrosis (IgG4-related RPF) often causes hydronephrosis requiring ureteral stenting. While glucocorticoid (GC) therapy is generally effective, predictors of successful stent removal remain unestablished. This re...
Rapidly enlarging intraocular inflammatory myofibroblastic tumor in an adult [0.03%]
成人眼内炎性肌纤维母细胞肿物的快速增大
Taku Inamoto,Hiroyuki Komatsu,Kinya Tsubota et al.
Taku Inamoto et al.
Intraocular inflammatory myofibroblastic tumor (IMT) is an extremely rare entity, and its clinical characteristics, immunopathological features, and optimal management remain insufficiently defined. A 57-year-old man presented with visual f...
Takafumi Kadono,Tomomitsu Miyagaki
Takafumi Kadono
Immune checkpoint inhibitors, represented by anti-PD-1 antibodies, anti-PD-L1 antibodies and anti-CTLA-4 antibodies, have brought significant therapeutic benefits to many patients with advanced-stage malignancies. By releasing inhibitory si...
Early steroid initiation may improve outcomes in immune checkpoint inhibitor-related cholangitis: a multicenter cohort study [0.03%]
早期使用皮质类固醇可能有助于改善免疫检查点抑制剂相关胆管炎的结局:一项多中心队列研究
Mayuko Kondo,Keisuke Ojiro,Makoto Ueno et al.
Mayuko Kondo et al.
Immune-checkpoint inhibitor (ICI)-related cholangitis is a rare but potentially fatal immune-related adverse event. In this study, we retrospectively analyzed 11 patients diagnosed with ICI-related cholangitis between 2020 and 2024 at Keio ...
Risk factors for adverse events or use of high-potency corticosteroids in non-infectious uveitis: a Japan claims database study (J-CAT2) [0.03%]
日本理赔数据库研究中的非感染性葡萄膜炎不良事件或使用高剂量皮质类固醇的风险因素(J-CAT2)研究
Sentaro Kusuhara,Koh-Hei Sonoda,Toshikatsu Kaburaki et al.
Sentaro Kusuhara et al.
The J-CAT2 study (#jRCT1030240195) aimed to evaluate treatment and patient factors associated with risk of complications/adverse events (AEs) or high corticosteroid exposure in patients with non-infectious uveitis (NIU) using advanced quant...
Achievement of intermediate treatment targets for Still's disease under tocilizumab treatment: a post-hoc analysis of the phase III trial [0.03%]
托珠单抗治疗Still病患者达到中期治疗目标的疗效分析:一项III期临床试验的事后分析研究
Koji Suzuki,Hideto Kameda,Kei Ikeda et al.
Koji Suzuki et al.
To evaluate the intermediate treatment targets for Still's disease proposed by EULAR/PReS recently, we conducted this post-hoc analysis of the Phase III trial of tocilizumab and its long-term extension to assess the achievement probability ...
Anti-striated muscle antibody positive anti-PD-1 antibody related myositis and cardiomyositis: an instructive autopsy case report with discussion for trigger of irAE [0.03%]
抗PD-1抗体相关肌炎和心肌炎阳性抗横纹肌抗体:伴有irAE触发因素讨论的尸检病例报告
Ayaka Kamada,Taichi Nomura,Terufumi Kubo et al.
Ayaka Kamada et al.
Immune checkpoint inhibitors (ICIs) can cause severe immune-related adverse events (irAEs), including life-threatening myositis and myocarditis. Characterizing the immunopathological features of these conditions is essential for improving c...